5F-PB-22

5F-PB-22
Legal status
Legal status
Identifiers
CAS Number
ChemSpider
Chemical and physical data
Formula C23H21FN2O2
Molar mass 376.42 g/mol
3D model (JSmol)

5F-PB-22 (5F-QUPIC or Quinolin-8-yl 1-pentyfluoro-1H-indole-3-8-carboxylate) is a designer drug which acts as a cannabinoid agonist.[1] The structure of 5F-PB-22 appears to have been designed with an understanding of structure-activity relationships within the indole class of cannabinoids.[2]

Pharmacology

5F-PB-22 acts as a full agonist with a binding affinity of 0.468nM at CB1 and 0.633nM at CB2 cannabinoid receptors.[3]

As of October 2015 5F-PB-22 is a controlled substance in China.[4]

In January 2014, 5F-PB-22 was designated as a Schedule I controlled substance in the United States after several deaths were associated with its use.[5][6]

In the United Kingdom, 5F-PB-22 is now classified and controlled as a Class B drug, following the November 2016 amendment to The Misuse of Drugs Act 1971. Several other synthetic cannabinoids structurally related to JWH-018, like 5F-PB-22, were also classified in this amendment. [7]

See also

References

  1. ↑ Banister, S. D.; Stuart, J.; Kevin, R. C.; Edington, A.; Longworth, M.; Wilkinson, S. M.; Beinat, C.; Buchanan, A. S.; Hibbs, D. E.; Glass, M.; Connor, M.; McGregor, I. S.; Kassiou, M. (2015). "Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135". ACS Chemical Neuroscience. 6 (8): 150508124201002. doi:10.1021/acschemneuro.5b00107. PMID 25921407.
  2. ↑ "5F-PB-22". Forendex. Retrieved 24 June 2015.
  3. ↑ Hess, Cornelius; Schoeder, ClaraT.; Pillaiyar, Thanigaimalai; Madea, Burkhard; Müller, ChristaE. (1 July 2016). "Pharmacological evaluation of synthetic cannabinoids identified as constituents of spice". Forensic Toxicology. 34 (2): 329–343. doi:10.1007/s11419-016-0320-2. ISSN 1860-8965. PMC 4929166. PMID 27429655.
  4. ↑ "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Retrieved 1 October 2015.
  5. ↑ Behonick, G; Shanks, K. G.; Firchau, D. J.; Mathur, G; Lynch, C. F.; Nashelsky, M; Jaskierny, D. J.; Meroueh, C (2014). "Four Postmortem Case Reports with Quantitative Detection of the Synthetic Cannabinoid, 5F-PB-22". Journal of analytical toxicology. 38 (8): 559–62. doi:10.1093/jat/bku048. PMC 4334789. PMID 24876364.
  6. ↑ Jordan Trecki; Roy R. Gerona; Michael D. Schwartz (July 2015). "Synthetic Cannabinoid–Related Illnesses and Deaths". New England Journal of Medicine. 373 (2): 103–107. doi:10.1056/NEJMp1505328. PMID 26154784.
  7. ↑ "The Misuse of Drugs Act 1971 (Amendment) Order 2016". www.legislation.gov.uk. Retrieved 2017-12-20.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.